Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
US Quantum Stocks Surge After $2 Billion Government Investment 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
Merck KGaA (ETR: MRCG) strengthened its full-year 2025 outlook after posting higher third-quarter earnings, supported by strong momentum in its Healthcare and Life Science divisions despite ongoing softness in the Electronics segment. The German science and technology company now expects net sales between €20.8 billion and €21.4 billion and EBITDA pre of €6 billion to €6.2 billion, reflecting organic growth of 3% and 5–7%, respectively.
The updated forecast also factors in portfolio changes, including the July 2025 acquisition of SpringWorks Therapeutics and the divestment of the Surface Solutions business. Merck projects earnings per share pre of €8.20 to €8.60, based on a 22% tax rate, and anticipates operating cash flow between €3.6 billion and €4 billion.
Merck said organic sales growth will be led primarily by its Life Science and Healthcare sectors, with Electronics expected to decline. Within Healthcare, the company foresees continued strength from its Cardiovascular, Metabolism & Endocrinology franchise. Meanwhile, multiple sclerosis treatment Mavenclad is set to remain a growth driver, although its contribution may soften after a recent U.S. court ruling that enables competing products.
In the third quarter, Merck’s net sales rose 1% to €5.32 billion, while EBIT increased 11.3% to €1.22 billion, lifting the margin to 23%. EBITDA pre climbed 3.1% to €1.67 billion, and profit after tax advanced 10.6% to €898 million. These gains were supported by divestment-related income, including a €113 million disposal gain from the Surface Solutions sale and proceeds from a $175 million FDA priority review voucher transaction.
Healthcare sales reached €2.2 billion, driven by strong performances from Mavenclad and oncology therapy Erbitux. Life Science revenue increased to €2.24 billion, supported by robust demand in Process Solutions. Electronics revenue declined 5.2% to €875 million following the divestment.
Merck ended the quarter with €1.52 billion in operating cash flow and net financial debt of €9.29 billion, reflecting new bond issuances and the SpringWorks acquisition. The company expects 2025 to remain volatile due to macroeconomic and currency factors, with the euro–U.S. dollar exchange rate likely staying between 1.11 and 1.15.
